An interventional study of iPeer2Peer Program in Heart Failure, sponsored by The Hospital for Sick Children. Recruiting at 1 site in Canada. Open to participants aged 12 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by The Hospital for Sick Children · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 454 studies in Heart Failure with a site in Canada — 77 open to participants now, 99 under way, 21 of them phase 3. Heart Failure · Canada.
Among the 454 studies in Heart Failure with a site in Canada, this one is the 280th largest by planned enrollment of the 362 interventional ones that give a count, is one of 27 that started in 2024, is one of 162 with no phase, reaches primary completion later than 48 of the 98 other live ones, and was the 387th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →77 of the 454 studies in Heart Failure with a site in Canada are open now. Recruiting first, the newest first:
AnaCardio AB · Sites in Canada, United States, Bulgaria and 5 more countries
Ages 18–85
Samantha Anthony · Sites in Canada
Ages 18–35
AstraZeneca · Sites in Canada, United States, Argentina and 29 more countries
Ages 18+
Ottawa Heart Institute Research Corporation · Sites in Canada
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 12 Years to 30 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
454 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 72 · Phase 3 106 · Phase 4 24
First in 1983; this study’s year is marked. 27 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 55 is below the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 226 across the 362 interventional studies, 360 across the 91 observational. Of the 307 that completed or were terminated, 127 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
201 of 454 have an industry lead sponsor. The 10 most frequent:
The Hospital for Sick Children is the lead sponsor of 579 studies on the registry; 81 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
The Hospital for Sick Children has 3 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
29 of the studies in Heart Failure with a site in Canada that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT05873881Phase 3Hamilton Health Sciences CorporationCOLchicine and Thiamine in Heart Failure Due to Ischemic Heart Disease | 2027-06 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06024746Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) | 2027-11 |
| NCT06008197Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | 2027-11 |
Add all 29 to your calendar (.ics) → With an account.
Among the 454 studies in Heart Failure with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The iPeer2Peer (iP2P) program is an online peer support mentorship program that provides modelling and reinforcement by trained young adult peer mentors to adolescent mentees with the same condition. A quasi-experimental single-arm pre-post study design will be employed across three sites. We will recruit 40 mentees (12-17 years of age) and 12-15 mentors (18-30 years of age) who will undergo training in mentoring and the use of eHealth technology. Mentor-mentee pairings will connect over 15 weeks through video calls and text messaging to provide peer support and encourage disease self-management skills. Data will be collected using standardized instruments and interviews across three time points.
Mentee inclusion criteria:
Mentor inclusion criteria:
Exclusion Criteria:
Participates in the iPeer2Peer program
Behavioral: iPeer2Peer Program
Behavioral: iPeer2Peer Support Mentorship Program is an online peer support mentorship program that has been established in multiple chronic disease populations as a self-management intervention, including chronic pain and juvenile idiopathic arthritis. The iPeer2Peer program provides modeling and reinforcement by pre-screened and trained young adult peer mentors to adolescent mentees.
Acceptability (Mentees)
Whether the innovation is agreeable, palatable or satisfactory
Time frame: 15 weeks after baseline/immediately after the intervention
Acceptability (Mentors)
Whether the innovation is agreeable, palatable or satisfactory
Time frame: Study completion, an average of 1 year
Adoption (Mentees)
The intention, initial decision or action to try or use an innovation
Time frame: Baseline to 12 weeks post-program completion
Adoption (Mentors)
The intention, initial decision or action to try or use an innovation
Time frame: Baseline to study completion, an average of 1 year
Feasibility (Mentees)
The extent to which an innovation can be used or carried out successfully in a given setting
Time frame: Baseline to 12 weeks post-program completion
Feasibility (Mentors)
The extent to which an innovation can be used or carried out successfully in a given setting
Time frame: Baseline to study completion, an average of 1 year
Appropriateness (Mentees)
The perceived fit, relevance or compatibility of the innovation for a practice setting; and/or its perceived fit to address an issue or problem
Time frame: Baseline to 12 weeks post-program completion
Appropriateness (Mentors)
The perceived fit, relevance or compatibility of the innovation for a practice setting; and/or its perceived fit to address an issue or problem
Time frame: Baseline to study completion, an average of 1 year
Level of engagement (Mentees)
Time frame: 15 weeks after baseline/immediately after the intervention
Level of engagement (Mentors)
Time frame: Study completion, an average of 1 year
Disease self-management skills (Mentees)
Time frame: Baseline to 12 weeks post-program completion
Adherence (Mentees)
Clinic attendance, completion of scheduled tests and procedures, and adolescent medication barriers scale
Time frame: Baseline to 12 weeks post-program completion
Quality of life (Mentees)
Time frame: Baseline to 12 weeks post-program completion
Perceived social support (Mentees)
Time frame: Baseline to 12 weeks post-program completion
Emotional distress (Mentees)
Time frame: Baseline to 12 weeks post-program completion
Resiliency (Mentees)
Time frame: Baseline to 12 weeks post-program completion
Assessment of mentor quality (Mentees)
Time frame: 15 weeks after baseline/immediately after the intervention
Physical and emotional symptoms (Mentors)
Time frame: Baseline to study completion, an average of 1 year
Perceived social role satisfaction (Mentors)
Time frame: Baseline to study completion, an average of 1 year
Self-efficacy (Mentors)
Time frame: Baseline to study completion, an average of 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Apr 2027, 39 months after the start.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 39 months is above that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Hospital for Sick Children →